LFWD

Lifeward

LFWD

Attention (50-day avg)0%

Attention rank (50-day avg)#3,450

Bullish sentiment (50-day avg)75%

Price to earnings ratio-0.4

Market capitalization19.6M

Earnings per share-14.7

Dividend yield (TTM)—

Revenue (annual)22M

Net income (annual)-19.9M

Social

What share of all stock conversation is about LFWD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jul 13

Lifeward Ltd. (LFWD) is considered a turnaround story with all pieces in place for profitability.
The company is currently being priced at face value, with a low float, making it a potentially attractive entry point.
The market's perception of LFWD's past is causing it to be undervalued, making it a low-risk opportunity.

Generated by AI

Sentiment

Of the messages about LFWD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	88.7% +4.42
Bearish	—	—	—	11.3% -4.42

Bullish· Dec 3

Lifeward Ltd. is a global leader in innovative medical technology, designed to transform the lives of people with physical limitations or disabilities.
The company has received prior authorization from Humana Medicare, indicating a positive development for the business.
Lifeward Ltd. has a micro float of 5 million shares, which could lead to significant price movements in the near future.

Bearish· Jun 25

$LFWD has dropped to a 52-week low despite recent news, suggesting a strong sell-off.
The company's warrant offering has led to a significant price drop, with some investors losing up to 50% of their money.
The market's reaction to the offering has been negative, with some analysts predicting that the stock could recover to $1 easily, but others warning of further declines.

Generated by AI

Topics

Of the messages about LFWD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	73.19%
Technical Analysis	—	—	—	13.04%
Analysts	—	—	—	2.9%
Controversies	—	—	—	0%
Earnings	—	—	—	8.33%
Macro	—	—	—	2.54%

Announcements· Mar 13

Lifeward Ltd. (LFWD) has received FDA 510(k) clearance for its ReWalk 7, the newest generation of its personal exoskeleton device for individuals with spinal cord injury.
The ReWalk 7 includes new features, enhancements, and upgrades, and is expected to expand workers' compensation access through an agreement with CorLife.
Lifeward's full-year revenue rose to $25.7 million, with ReWalk Personal Exoskeleton sales increasing by 130% in 2024, driven by recently established Medicare coverage.

Technical Analysis· Mar 13

$LFWD is showing early signs of bullish momentum, with a 25% increase since landing on a scanner, and clear signs of momentum are showing.
A solid 10% gain for $LFWD since it first appeared on a radar, with the RSI and MACD indicators suggesting whether this momentum is sustainable.
$LFWD has broken up a bullish flag, with the momentum showing no signs of slowing, and a remarkable 50% increase since initial mention.

Generated by AI

Community

Of the messages about LFWD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	40%	36.36%	30.73%
Newcomers	100%	60%	63.64%	69.27%

Jun 25

Newcomers are excited about a recent court ruling that determined the ReWalk Personal Exoskeleton is "reasonable and necessary" for Medicare beneficiaries, potentially increasing access for paralyzed patients.
Some newcomers are shorting the stock, citing past instances where the company pumped the stock before offering new shares, and are now waiting for a potential price drop.
Others are bearish on the stock, stating that it has reached a new low and that investors who bought into the company's good news are now "boned" or in trouble.

Generated by AI

News

Lifeward sets date for 2026 annual and extraordinary shareholder meeting

14d agoInvesting.com

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP)

18d agoSeeking Alpha

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that an updated investor presentation is available on the Company's investor relations website. The presentation provides an overview of Lifeward's strategy to scale its established rehabilitation platform, levera

21d agoYahoo Finance

Lifeward Announces Major CEO and CFO Leadership Changes

Detailed price information for Lifeward Ltd (LFWD-Q) from The Globe and Mail including charting and trades.

28d agoThe Globe and Mail

Lifeward names Josh Hexter interim CEO, Rami Aviram as CFO

29d agoInvesting.com

Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO

1mo agoYahoo Finance

Also Discussed

Investors talking about LFWD also mention

#	Name	Attention
1	Ekso Bionics Holdings, Inc.EKSO	0%new
2	Eltek Ltd.ELTK	0%new
3	Bio-Path Holdings Inc.BPTH	0%0
4	Biodexa Pharmaceuticals plc ADRBDRX	0%+0
5	Stabilis Solutions Inc.SLNG	0%0
6	OBLN - Obalon Therapeutics, Inc.	——
7	Argent Mid Cap ETFAMID	0%0
8	ELVT - Elevate Credit, Inc.	——
9	ABIO - ARCA biopharma, Inc.	——
10	Legacy Education Inc.LGCY	0%new

Lifeward Ltd.

Healthcare
Medical Devices

Lifeward Ltd. is a medical device company that develops and commercializes rehabilitation technologies designed to improve mobility and support recovery for people with physical and neurological conditions. Its portfolio includes wearable robotic exoskeletons and related systems used in clinical, home, and community settings. Key products include the ReWalk personal exoskeleton, the ReStore soft exo-suit, the AlterG Anti-Gravity System, and MyoCycle devices, which are used in physical rehabilitation, post-stroke recovery, and mobility training. The company also serves institutions and individual users through direct sales and third-party distribution channels. Lifeward Ltd. operates across markets in the United States, Europe, and the Asia-Pacific region, positioning itself within the broader medical technology and rehabilitation equipment sector.

Website

Location

3 Hatnufa St.

Yokneam Illit, 2069203

Israel

Social

What share of all stock conversation is about LFWD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jul 13

Lifeward Ltd. (LFWD) is considered a turnaround story with all pieces in place for profitability.
The company is currently being priced at face value, with a low float, making it a potentially attractive entry point.
The market's perception of LFWD's past is causing it to be undervalued, making it a low-risk opportunity.

Generated by AI

Sentiment

Of the messages about LFWD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	88.7% +4.42
Bearish	—	—	—	11.3% -4.42

Bullish· Dec 3

Lifeward Ltd. is a global leader in innovative medical technology, designed to transform the lives of people with physical limitations or disabilities.
The company has received prior authorization from Humana Medicare, indicating a positive development for the business.
Lifeward Ltd. has a micro float of 5 million shares, which could lead to significant price movements in the near future.

Bearish· Jun 25

$LFWD has dropped to a 52-week low despite recent news, suggesting a strong sell-off.
The company's warrant offering has led to a significant price drop, with some investors losing up to 50% of their money.
The market's reaction to the offering has been negative, with some analysts predicting that the stock could recover to $1 easily, but others warning of further declines.

Generated by AI

Topics

Of the messages about LFWD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	73.19%
Technical Analysis	—	—	—	13.04%
Analysts	—	—	—	2.9%
Controversies	—	—	—	0%
Earnings	—	—	—	8.33%
Macro	—	—	—	2.54%

Announcements· Mar 13

Lifeward Ltd. (LFWD) has received FDA 510(k) clearance for its ReWalk 7, the newest generation of its personal exoskeleton device for individuals with spinal cord injury.
The ReWalk 7 includes new features, enhancements, and upgrades, and is expected to expand workers' compensation access through an agreement with CorLife.
Lifeward's full-year revenue rose to $25.7 million, with ReWalk Personal Exoskeleton sales increasing by 130% in 2024, driven by recently established Medicare coverage.

Technical Analysis· Mar 13

$LFWD is showing early signs of bullish momentum, with a 25% increase since landing on a scanner, and clear signs of momentum are showing.
A solid 10% gain for $LFWD since it first appeared on a radar, with the RSI and MACD indicators suggesting whether this momentum is sustainable.
$LFWD has broken up a bullish flag, with the momentum showing no signs of slowing, and a remarkable 50% increase since initial mention.

Generated by AI

Community

Of the messages about LFWD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	40%	36.36%	30.73%
Newcomers	100%	60%	63.64%	69.27%

Jun 25

Newcomers are excited about a recent court ruling that determined the ReWalk Personal Exoskeleton is "reasonable and necessary" for Medicare beneficiaries, potentially increasing access for paralyzed patients.
Some newcomers are shorting the stock, citing past instances where the company pumped the stock before offering new shares, and are now waiting for a potential price drop.
Others are bearish on the stock, stating that it has reached a new low and that investors who bought into the company's good news are now "boned" or in trouble.

Generated by AI

Lifeward

Social

Jul 13

Bullish· Dec 3

Bearish· Jun 25

Announcements· Mar 13

Technical Analysis· Mar 13

Jun 25

Lifeward sets date for 2026 annual and extraordinary shareholder meeting

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP)

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy

Lifeward Announces Major CEO and CFO Leadership Changes

Lifeward names Josh Hexter interim CEO, Rami Aviram as CFO

Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO

Also Discussed

Lifeward Ltd.

Company Information

Location

Lifeward sets date for 2026 annual and extraordinary shareholder meeting

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP)

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy

Lifeward Announces Major CEO and CFO Leadership Changes

Lifeward names Josh Hexter interim CEO, Rami Aviram as CFO

Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO

Also Discussed

Social

Jul 13

Bullish· Dec 3

Bearish· Jun 25

Announcements· Mar 13

Technical Analysis· Mar 13

Jun 25